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I will discuss the following off-label use and/or 
investigational use in my presentation: Quantitative 
Computed Tomography.
Does spaceflight result in irreversible changes to 
bone that combine with age-related losses?
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Consequence: Premature Fractures?
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Perception:  Subclinical data may not 
justify some RESEARCH particularly  ,  
studies which may introduce greater 
i k/b fitr s ene .
RMAT drives the need for a forum 
t i t tho commun ca e e 
UNCERTAINTIES to Space Medicine.
Why does this uncertainty exist?    
• DXA BMD T-score: Widely-applied surrogate for bone strength and 
for fracture risk because grounded in abundance of population        -
based fracture data.
• Provides a relative risk for fracture – not enough information to 
assess probability fracture per individual which has greater clinical 
utility – the “so what?” question.
• Bone strength is influenced by factors that are not measured by           
DXA BMD (population data).
• Limitations of DXA technology
• Understudied cohort: younger, predominantly male, astronauts who 
are exposed to unique risk factor – spaceflight.*
Reported “Disconnects” and 
Limitations of DXA BMD
• Riggs BL et al.  Effect of fluoride treatment on the fracture rate in postmenopausal 
women with osteoporosis.  N Engl J Med 322(12):802-809, 1990.
• Riggs BL et al.  Clinical trial of fluoride therapy in postmenopausal osteoporotic 
women:  extended observations and additional analysis.  J Bone Miner Res.  
9(2):265-275, 1994.
• Cummings SR et al.  Effect of alendronate on risk of fracture in women with low 
bone density but without vertebral fractures: results from the Fracture Intervention            
Trial.  JAMA 1998  280(24):2119-2120.
• Gutteridge DH et al.  A randomized trial of sodium fluoride (60 mg) +/- estrogen in 
postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and 
peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral          
loss, but not vertebral fractures.  Osteoporosis Int 13(2):158-170, 2002.  
• Black DM et al.   The effects of parathyroid hormone and alendronate alone or in 
combination in postmenopausal osteoporosis.  N Engl J Med  349(13):1207-1215, 
2003 (DXA does not pick up significant impact of PTH detected by QCT ).             .
• Chesnut CH et al.  Effects of salmon calcitonin on trabecular microarchitecture as 
determined by magnetic resonance imaging: results from the QUEST study.  J Bone 
Miner Res. 2005 Sep;20(9):1548-61.
• Lang T et al.  Cortical and trabecular bone mineral loss from the spine and hip in 
long-duration spaceflight.  J Bone Miner Res. 2004 Jun;19(6):1006-12.
After 40+ years in space, 
bone risk remains poorly understood    .
• “Osteoporosis is a skeletal disorder characterized by compromised 
bone strength predisposing to an increased risk of fracture.  Bone 
strength reflects the integration of two main features:  bone density 
and bone quality ”  .
JAMA.  2001
• “….Bone quality, in turn, is stated to refer to architecture, turnover, 
damage accumulation, (e.g., microfractures) and mineralization….”
•
Osteoporosis Int 2002 .  
One limitation: DXA does not account for different 
bone geometries.
(g/cm2)
Mary Bouxsein, Ph.D. Bone Geometry and Skeletal Fragility, May 2005
Why does this uncertainty exist?    
• Widely-applied index for bone strength and fracture risk (DXA BMD 
T ) d d i b d f l i b d f d-score  groun e  n a un ance o  popu at on- ase  racture ata.
• Provides a relative risk for fracture – not enough information to 
b bilit f t i di id l hi h h t li i lassess pro a y rac ure per n v ua w c  as grea er c n ca  
utility – the “so what?” question.
• Bone strength is influenced by factors that are not measured by           
DXA BMD. 
• Limitations of DXA technology   
• Understudied cohort: younger, predominantly male, astronauts who 
are exposed to unique risk factor – spaceflight *     .
DXA BMD @ Johnson Space Center     
• Monitor astronaut skeletal health    
• Characterize skeletal effects of spaceflight
E l t ffi f i fli ht• va ua e e cacy o  n- g  
countermeasures
• Verify restored health status
Does Medical Operations need a “new line 
in the sand” for skeletal integrity? YES     
RMAT – Index for Skeletal Integrity     
• Human Health and • HOW STRONG DO BONES HAVE TO BE AND HOW LOW CAN IT GO
Performance 
Standard
        
TO PERFORM MISSION TASKS? TO 
AVOID PREMATURE AGE-RELATED 
FRACTURES?
• Selection & 
Retention 
• WHAT IS THE CUTOFF RANGE FOR 
FLIGHT  IN LIGHT OF EXPECTED 
SKELETAL ASSAULT WITH 
SPACEFLIGHT? Specific
• Clinical Risk 
Trigger(s)
  
architecture
• WHAT IS THE PHYSIOLOGICAL 
MEASURE THAT REQUIRES A  
CLINICAL RESPONSE 
• Current Mitigation 
  or 
INTERVENTION?
• WHAT INDEX FOR EFFICACY?Strategy    
Bone Summit Activity
to recommend clinical practice guidelines for risk 
management.
R i ALL i f ti * i di id l b i th t ld i t• ev ew n orma on  on n v ua  as s a  wou  ass s  
clinical experts to understand
1) Why BMD changes in long-duration astronaut     ,
2) How those changes may relate to the spaceflight
3) How those changes may influence the probability for fracture:  1) 
premature age-related fractures and 2) fractures with typical preflight
physical activity
• All of these requirements could not be met.  Still, Bone Summit 
provides opportunity to recommend forward actions
Requirements for a Bone Summit Panel     
• Add photo
• Specific expertise 
 BMD in clinical practice
 Leaders in field and 
policy-makers
 Clinical expertise: l  ma e 
osteoporosis, bone turnover 
markers, bone epidemiology, 
endocrinology exercise, , 
vitamin D
Overarching themes that influenced 
l d tipane  recommen a ons.
1 U lik l f NASA b i h l f d ll i d. n e y or  to o ta n t e vo ume o  ata  norma y requ re  to 
formulate bone health policies.
2 Rare poorly understood health risk in an unique population. ,          
because of the very limited dataset.
3. Surveillance data required to increase the understanding of 
fli ht ff t d d t i t b bilit f f tspace g  e ec s an  re uce uncer a n y re: pro a y o  rac ure.
Given NASA’s constraints these may be circumstances by   ,      
which research technologies and analyses are 
transitioned to the clinical realm.
Recommendation: Index for decision-
ki (i di l t d d ) b dma ng .e., me ca  s an ar s  ase  
upon estimates of strength not surrogate 
measure, e.g., BMD.
How should bone strength be 
estimated?
Estimate hip bone strength by Finite Element 
Modeling (a comp tational tool)u .
G t Materialeome ry  Properties
Finite 
Element
BMD Loading
 
Strength
Individualized
Keyak et al, 1998, 2001, 2005
Fracture Risk
Slide courtesy of P. Truszkowski
FEM – a computational tool that uses QCT data to 
estimate Hip bone strength
QCT estimates fracture loads
R2=.66
QCT
better than DXA 
QCT + FEM has superior         
capabilities for estimating fracture 
loads
R2 =.57
DXA
R2 =.84DD Cody:  Femoral strength is better predicted  
FEMby finite element models than QCT and DXA. J 
Biomechanics  32:1013 1999.
Astronaut Data: Surrogates of bone 
t th d t l t
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Summary & Conclusion  
• Multiple levels of uncertainty with NASA’s current 
assessment of skeletal integrity    
• The RMAT-the driver to identify a clinical trigger and 
lti t l t d l i d f k l t l i t itu ma e y, o eve op an n ex or s e e a  n egr y
• Required RMAT indices led to Action to convene Bone         
Summit Panel for clinical practice recommendations to 
manage occupational risks
• NASA needs to consider innovative research technology 
and analyses (with translation to fracture risk) to improve 
it ti ti f f t b bilit i LD t ts es ma on o  rac ure pro a y n  as ronau s.
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Individual Results from ISS
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Individual Results from ISS
F ll L dia  oa ng (3 gain to 24% loss in strength)
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QCT:  Trabecular BMD at Femoral neck does not 
appear to show a recovery 2 to 4 years postflight         
QCT Extension Study (n=8) Postflight Trabecular BMD in hip.  Carpenter, D et al. Acta Astronautica, 2010.
